Real-world short-term outcomes and treatment regimen comparisons in patients with metastatic renal cell carcinoma treated with first-line immune combinations

Abstract Background Immune-combinations have recently become the standard first-line treatment for patients with metastatic renal cell carcinoma (mRCC). This study evaluated the applicability of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model in predicting out...

Full description

Bibliographic Details
Published in:BMC Cancer
Main Authors: Masato Kikuta, Sei Naito, Takahiro Osawa, Kazuyuki Numakura, Takafumi Narisawa, Yuki Takai, Mayu Yagi, Yuya Sekine, Ojiro Tokairin, Nobuo Shinohara, Tomonori Habuchi, Norihiko Tsuchiya
Format: Article
Language:English
Published: BMC 2025-01-01
Subjects:
Comparison
Immunotherapy
Immune-combinations
Prognosis
Renal cell carcinoma; Tyrosine kinase inhibitor
Online Access:https://doi.org/10.1186/s12885-025-13504-6

Internet

https://doi.org/10.1186/s12885-025-13504-6

Similar Items